Literature DB >> 8193349

Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia.

X Sun1, B Evatt, J H Griffin.   

Abstract

A coagulation test abnormality, termed activated protein C (APC) resistance, involving poor anticoagulant response to APC is currently the most common laboratory finding among venous thrombophilic patients. Because the anticoagulant activity of APC involves inactivation of factors Va and VIIIa, studies were made to assess the presence of abnormal factors V or VIII. Diluted aliquots of plasma from two unrelated patients with APC resistance and thrombosis were added to either factor VIII-deficient or factor V-deficient plasma and APC resistance assays were performed. The results suggested that patients' factor V but not factor VIII rendered the substrate plasma APC resistant. When factor V that had been partially purified from normal or APC resistant patients' plasmas using immunoaffinity chromatography was added to factor V-deficient plasma, APC resistance assays showed that patients' factor V or factor Va, but not normal factor V, rendered the substrate plasma resistant to APC. Studies of the inactivation of each partially purified thrombin-activated factor Va by APC suggested that half of the patients' factor Va was resistant to APC. These results support the hypothesis that the APC resistance of some venous thrombophilic plasmas is caused by abnormal factor Va.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8193349

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

1.  Prothrombotic phenotype of protein Z deficiency.

Authors:  Z F Yin; Z F Huang; J Cui; R Fiehler; N Lasky; D Ginsburg; G J Broze
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

2.  An assessment of the comparative utility of functional and molecular level analyses in the investigation of patients with thrombophilia.

Authors:  B Clark; C Caine; E N McSweeney; B A McVerry; H C Gooi
Journal:  Clin Mol Pathol       Date:  1996-08

3.  Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C.

Authors:  J Petäjä; J A Fernández; A Gruber; J H Griffin
Journal:  J Clin Invest       Date:  1997-06-01       Impact factor: 14.808

4.  Factor V Leiden related Budd-Chiari syndrome.

Authors:  P Deltenre; M H Denninger; S Hillaire; M C Guillin; N Casadevall; J Brière; S Erlinger; D C Valla
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

5.  Binding sites for blood coagulation factor Xa and protein S involving residues 493-506 in factor Va.

Authors:  M J Heeb; Y Kojima; T M Hackeng; J H Griffin
Journal:  Protein Sci       Date:  1996-09       Impact factor: 6.725

6.  Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene.

Authors:  C Aparicio; B Dahlbäck
Journal:  Biochem J       Date:  1996-01-15       Impact factor: 3.857

7.  Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C.

Authors:  B Zöller; P J Svensson; X He; B Dahlbäck
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

8.  Blood coagulation factors V and VIII: Molecular Mechanisms of Procofactor Activation.

Authors:  Mettine H A Bos; Rodney M Camire
Journal:  J Coagul Disord       Date:  2010-07-01

Review 9.  Occlusive vascular diseases in oral contraceptive users. Epidemiology, pathology and mechanisms.

Authors:  I F Godsland; U Winkler; O Lidegaard; D Crook
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

10.  Thrombophilia Due to Factor V and Factor II Mutations and Formation of a Dural Arteriovenous Fistula: Case Report and Review of a Rare Entity.

Authors:  Sam Safavi-Abbasi; Federico Di Rocco; Peter Nakaji; Guenther C Feigl; Alireza Gharabaghi; Madjid Samii; Anton Valavanis; Amir Samii
Journal:  Skull Base       Date:  2008-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.